1 / 17

State of the States Prescription Drug Abuse and Overdose Policy

State of the States Prescription Drug Abuse and Overdose Policy. Christopher M. Jones, PharmD, MPH LCDR, US Public Health Service Division of Unintentional Injury Prevention National Center for Injury Prevention and Control Centers for Disease Control and Prevention.

kalin
Download Presentation

State of the States Prescription Drug Abuse and Overdose Policy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. State of the States Prescription Drug Abuse and Overdose Policy Christopher M. Jones, PharmD, MPH LCDR, US Public Health ServiceDivision of Unintentional Injury Prevention National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division of Unintentional Injury Prevention

  2. Overview • Current Policy Strategies • State laws/regulations • PDMPs • Prescribing Guidelines • Policy Strategy Trends

  3. Doctor Shopping Laws CDC PHLP 2013

  4. Tamper Resistant Forms CDC PHLP 2013

  5. Physical Exam Requirements CDC PHLP 2013

  6. Patient ID Requirements CDC PHLP 2013

  7. Pill Mill Laws CDC PHLP 2013

  8. Prescription Limits CDC PHLP 2013

  9. Immunity from Prosecution CDC PHLP 2013

  10. Prescribing Guidelines • Prescribing guidelines • Washington – Rule • Utah • New Mexico • Oklahoma • NYC ED prescribing guidelines • Washington • Ohio • Oklahoma • Arkansas • Oregon • Maine • NYC

  11. PDMPs and Health Information Technology • Interoperability • Active – Alabama, Arizona, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Michigan, New Mexico, North Dakota, Ohio, South Carolina, South Dakota, Virginia • In Process – California, Colorado, Delaware, Idaho, Massachusetts, Minnesota, Mississippi, Montana, Nevada, New Jersey, North Carolina, Rhode Island, Texas, Utah, Washington, West Virginia • EHR Integration • Florida, Illinois, Indiana, Kansas, Maine, Ohio, Texas, Washington, West Virginia PDMP CoE at Brandeis University, NABP PMPi, MITRE Corp, SAMHSA

  12. PDMP Proactive Reporting PDMP CoE Brandeis University. 2013.

  13. Top 10 Proposed Legislation • Immunity from prosecution laws and/or naloxone – 21 states • Required use/registration of PDMP – 13 states • PDMP enhancements (access, reporting time, delegates) – 11 states • Creation of Commission or Working Group – 9 states • Mandatory provider education on pain/addiction – 7 states • Abuse-deterrent formulation substitution restrictions – 6 states • Opioid prescribing standards/rules – 5 states • PDMP funding – 4 states • OTP standards – 4 states • Quantity/dose limits – 2 states CQ State Tracker, CDC PHLP. 2013

  14. Honorable Mentions • Alaska – required consultation with pain management specialist prior to prescribing ≥ 120 MME of an opioid • Iowa – promulgate rules/regulations on opioid prescribing in the ED • New Mexico – rescheduling hydrocodone • West Virginia - Prohibit prescribing of OxyContin or fentanyl unless the product also contains naloxone CQ State Tracker, CDC PHLP. 2013

  15. Conclusions • State level policies can significantly impact the prescription drug overdose epidemic • Many states are instituting similar policies…no need to recreate the wheel • Robust evaluations of policies and dissemination of findings are critical

  16. The findings and conclusions in this report are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention. Thank You Christopher M. Jones, PharmD, MPH cjones@cdc.gov

More Related